Dr. Reddy's delays semaglutide supply due to ingredient issues, impacting shares but posing no safety risks.
More than half a dozen Indian drugmakers have launched
lower-cost copies of Novo Nordisk’s Ozempic and Wegovy, vying
for a share of the fast-growing global obesity treatment market
| Photo Credit:
quantic69
Dr. Reddy’s delays semaglutide supplies over quality issues, causing shares to drop amid ongoing investigations and commitment to…
Dr. Reddy’s delays semaglutide supplies over quality issues, causing shares to drop amid ongoing investigations and commitment to…
Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to…
Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a…
No impact on patient safety or on the product’s existing global regulatory filings
Dr Reddy's delayed Semaglutide supplies after certain batches failed quality specifications due to an API issue. The company said…
Dr. Reddy’s to delay semaglutide supplies due to quality issue, shares hit
Dr. Reddy’s to delay semaglutide supplies due to quality isssue, shares hit
Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies
Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concerns
Dr. Reddy’s halts semaglutide supplies on quality concerns, shares plunge, Torrent recalls product
Wegovy, Ozempic regain weight as Indian generics fall behind
